Pfizer Inc. (PFE) — closed signal from December 28, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 28, 2026.
Predicted vs. what happened
What happened
Reached its target in 44 days.
The thesis — published December 28, 2025
Pfizer looks like a safer stock that pays a high dividend and may bounce back because it has been sold too hard. News points to it being cheap and the roughly 6.8% dividend attracts income investors. But watch for healthcare headlines and legal or regulatory problems; keep expectations modest and define your risk level.
Primary drivers
- High dividend around 6.8% attracts income buyers
- Cheap stock framing can draw investors looking for value
- Being oversold makes a short-term rebound likely
- Healthcare stocks often fall less in market stress
How it played out
PFE: target reached in 44 days
Lyra published PFE at 25.09 on 2025-12-28 with a short-term thesis for 10% growth toward 27.60. The thesis pointed to a dividend around 6.8%, a cheap stock framing, an oversold setup, and the idea that healthcare stocks often fell less in market stress.
Inside the window, PFE reached 27.94 on 2026-02-11, above the 27.60 target. That took 44 days. The peak gain was 11.4%. By 2026-03-28, it ended at 27.04, below the peak but still above the publication price. The thesis played out.
What happened during the window
On 2026-02-03, Pfizer reported fourth-quarter sales of $17.56 billion and adjusted earnings of 66 cents a share. The company also reiterated its 2026 revenue guidance of $59.5 billion to $62.5 billion.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.